APOL1 Gene Variations for Kidney Disease
(APOLLO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve kidney transplant outcomes by examining how variations in the APOL1 gene affect kidney health. Certain versions of this gene increase susceptibility to kidney disease, particularly among individuals with recent African ancestry. Researchers will test DNA from living kidney donors to assess the impact of these gene variations on transplant success. Living kidney donors with African American, Afro-Caribbean, Hispanic Black, or African heritage may be suitable candidates for this study. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could enhance kidney transplant success for future patients.
Why are researchers excited about this trial?
Researchers are excited about the APOLLO trial because it aims to uncover how genetic factors, specifically APOL1 gene variations, affect long-term outcomes in kidney transplant recipients. Unlike current treatments that focus primarily on medication and surgical techniques to improve transplant success, this trial seeks to understand the genetic influences, potentially leading to personalized treatment plans. By identifying the impact of these genetic variations, the study could pave the way for more targeted and effective strategies to enhance kidney transplant outcomes for patients with specific genetic profiles.
Who Is on the Research Team?
David M. Reboussin, PhD
Principal Investigator
Wake Forest University Health Sciences
Paul L. Kimmel, MD
Principal Investigator
Natl Institute of Diabetes, Digestive & Kidney Diseases
Barry I. Freedman, MD
Principal Investigator
Wake Forest University Health Sciences
Marva Moxey-Mims, MD
Principal Investigator
Children's Natl Health System; George Washington Univ Sch of Med and Health Serv
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
DNA Testing
DNA from kidney donors and recipients is tested for APOL1 gene variants to determine effects on kidney transplant-related outcomes
Follow-up
Participants are monitored for safety and effectiveness after kidney transplantation, focusing on renal allograft outcomes and donor health
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
National Institutes of Health (NIH)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.